NSE
Beta Drugs LimitedBETA
Beta Drugs Limited is a pharmaceutical company engaged in the development, manufacture, and marketing of generic medicines. The company focuses on providing affordable healthcare solutions.
| Key products | Generic Medicines, Pharmaceuticals |
|---|---|
| Geography | India, Middle East, Africa |
| Competitors | Cipla Ltd, Sun Pharma, Dr. Reddy's Laboratories |
AI-generated overview — verify before relying on it.
Net institutional flow
+₹26.3 Cr
Institutional buyers
1 in / 0 out
High-impact filings
0 · tilt Neutral
Next corporate action
—
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | ATALREAL | +₹7.2 Cr | 157 | — | — | — | — |
| 2 | QUADFUTURE | +₹0.1 Cr | 148 | — | — | — | — |
| 3 | MOBIKWIK | +₹0.1 Cr | 83 | — | — | — | — |
| 4 | BETAThis | — | — | — | — | — | — |
| 5 | MTNL | +₹0 Cr | 2 | — | — | — | — |
| 6 | GATECH | +₹0 Cr | 8 | — | — | — | — |
| 7 | IRMENERGY | −₹2.2 Cr | 328 | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
SWOT
Strengths
- • Established presence in the Indian pharmaceutical market
- • Diversified portfolio of generic medicines
- • Strong distribution network
- • Research and development capabilities
Weaknesses
- • Dependence on a few key products
- • Competition from established players
- • Regulatory challenges
- • High operating costs
Opportunities
- • Growing demand for affordable healthcare solutions in India
- • Expansion into new markets such as Africa and Southeast Asia
- • Increasing focus on research and development of innovative generics
- • Potential for partnerships with pharmaceutical companies
Threats
- • Intensifying competition from generic medicines
- • Rising regulatory scrutiny and compliance costs
- • Fluctuating raw material prices
- • Impact of COVID-19 pandemic on global healthcare demand
AI-generated from our data — verify before relying on it.
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
- 3
- 3
No bulk/block deals for BETA in this window.
Results & transcripts
Financial results
None yet.
Calls & transcripts
- Significant increase in volume has been observed in Beta Drugs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Beta Drugs Limited has submitted their response. (PDF) →
- Significant increase in volume has been observed in Beta Drugs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited. (PDF) →
News & chatter on BETA
RSS News
0No recent news.
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.